Bioequivalence and Bioavailability Forum 01:55 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

CFDA: Draft guidance? [RSABE / ABEL]

posted by libaiyi - China, 2018-06-13 03:39 - Posting: # 18895
Views: 681

Thanks for you reply.

Another question,
how to write the null hypothesis and alternative hypothesis for BE based on FDA or EMA method?

Complete thread:

Calculate the BE limits for HVDPs based on EMA - libaiyi, 2018-06-08 11:41 [RSABE / ABEL]
- Calculate the BE limits for HVDPs based on EMA - Shuanghe, 2018-06-08 12:51
- (Expanded) BE limits, EMA-style - Helmut, 2018-06-08 13:19
  - (Expanded) BE limits, EMA-style - libaiyi, 2018-06-11 07:21
    - CFDA: Yet another story? - Helmut, 2018-06-11 12:24
      - CFDA: Yet another story? - libaiyi, 2018-06-12 11:09
        
        CFDA: Draft guidance? - Helmut, 2018-06-12 14:54
        
        CFDA: Draft guidance? - libaiyi, 2018-06-13 03:39
        
        Hypotheses generated “in face of the data” - Helmut, 2018-06-13 11:39
        
        Hypotheses generated “in face of the data” - libaiyi, 2018-06-14 03:46

Bioequivalence and Bioavailability Forum | Admin contact
18,698 posts in 3,983 threads, 1,234 registered users;
online 12 (0 registered, 12 guests [including 10 identified bots]).

When puzzled, it never hurts to read the primary documents –
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience. Stephen Jay Gould

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by

Ing. Helmut Schütz